Published in Blood on November 27, 2002
Novel and unexpected clearance mechanisms for cold platelets. Transfus Apher Sci (2009) 1.08
Pathogen Inactivation of Platelet and Plasma Blood Components for Transfusion Using the INTERCEPT Blood System™ Transfus Med Hemother (2011) 1.04
Obstacles of Multiplex Real-Time PCR for Bacterial 16S rDNA: Primer Specifity and DNA Decontamination of Taq Polymerase. Transfus Med Hemother (2010) 1.03
Extended storage of platelet-rich plasma-prepared platelet concentrates in plasma or Plasmalyte. Transfusion (2010) 0.95
Pathogen inactivation technologies for cellular blood components: an update. Transfus Med Hemother (2014) 0.90
Annexin V Release and Transmembrane Mitochondrial Potential during Storage of Apheresis-Derived Platelets Treated for Pathogen Reduction. Transfus Med Hemother (2010) 0.87
Profiling alterations in platelets induced by Amotosalen/UVA pathogen reduction and gamma irradiation--a LC-ESI-MS/MS-based proteomics approach. Blood Transfus (2012) 0.87
Evaluation of White Blood Cell- and Platelet-Derived Cytokine Accumulation in MIRASOL-PRT-Treated Platelets. Transfus Med Hemother (2009) 0.86
Current methods for the reduction of blood-borne pathogens: a comprehensive literature review. Blood Transfus (2013) 0.83
Development of the S-303 Pathogen Inactivation Technology for Red Blood Cell Concentrates. Transfus Med Hemother (2011) 0.83
Effects of pathogen reduction systems on platelet microRNAs, mRNAs, activation, and function. Platelets (2014) 0.81
Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation. Cochrane Database Syst Rev (2015) 0.80
Biological response modifiers in photochemically pathogen-reduced versus untreated apheresis platelet concentrates. Transfusion (2012) 0.80
Application of reticulated platelets to transfusion management during autologous stem cell transplantation. Onco Targets Ther (2012) 0.80
A prospective, active haemovigilance study with combined cohort analysis of 19 175 transfusions of platelet components prepared with amotosalen-UVA photochemical treatment. Vox Sang (2015) 0.77
Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation. Cochrane Database Syst Rev (2015) 0.77
In vitro evaluation of pooled buffy coat platelets treated with photochemical pathogen inactivation using amotosalen. Vox Sang (2004) 0.77
A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation. Cochrane Database Syst Rev (2015) 0.76
Photochemical inactivation of chikungunya virus in human apheresis platelet components by amotosalen and UVA light. Am J Trop Med Hyg (2013) 0.75
Pathogen-reduced platelets for the prevention of bleeding. Cochrane Database Syst Rev (2017) 0.75
Pathogen reduction through additive-free short-wave UV light irradiation retains the optimal efficacy of human platelet lysate for the expansion of human bone marrow mesenchymal stem cells. PLoS One (2017) 0.75
Amotosalen/UVA pathogen inactivation technology reduces platelet activatability, induces apoptosis and accelerates clearance. Haematologica (2017) 0.75
Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells (2006) 8.61
High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med (2007) 5.84
New susceptibility locus for coronary artery disease on chromosome 3q22.3. Nat Genet (2009) 5.12
Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med (2003) 4.90
Factors associated with overall and attributable mortality in invasive aspergillosis. Clin Infect Dis (2008) 3.18
Flexible, foldable, actively multiplexed, high-density electrode array for mapping brain activity in vivo. Nat Neurosci (2011) 3.03
Critical parameters for the isolation of mesenchymal stem cells from umbilical cord blood. Stem Cells (2004) 2.88
How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood (2009) 2.86
Positive and negative network correlations in temporal lobe epilepsy. Cereb Cortex (2004) 2.73
Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. Blood (2013) 2.42
Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J Clin Oncol (2002) 2.31
Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis (2011) 2.19
Human alternatives to fetal bovine serum for the expansion of mesenchymal stromal cells from bone marrow. Stem Cells (2009) 2.19
Challenges with advanced therapy medicinal products and how to meet them. Nat Rev Drug Discov (2010) 2.09
Human AB serum and thrombin-activated platelet-rich plasma are suitable alternatives to fetal calf serum for the expansion of mesenchymal stem cells from adipose tissue. Stem Cells (2007) 2.09
NK cell responses to cytomegalovirus infection lead to stable imprints in the human KIR repertoire and involve activating KIRs. Blood (2013) 2.04
Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC). Haematologica (2007) 2.03
Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood (2005) 2.01
Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood (2005) 1.94
Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study. Haematologica (2010) 1.91
Improved survival after allogeneic hematopoietic stem cell transplantation in recent years. A single-center study. Biol Blood Marrow Transplant (2011) 1.90
Messenger RNA profiling of human platelets by microarray hybridization. Thromb Haemost (2003) 1.87
2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis (2014) 1.81
Bone marrow harvest versus peripheral stem cell collection for haemopoietic stem cell donation in healthy donors. Cochrane Database Syst Rev (2009) 1.74
Fully automated processing of buffy-coat-derived pooled platelet concentrates. Transfusion (2004) 1.72
2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis (2013) 1.69
Circulation of genotype 4 hepatitis E virus in Europe: first autochthonous hepatitis E infection in France. J Clin Virol (2012) 1.65
Transfusion guidelines for neonates and older children. Br J Haematol (2004) 1.61
Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients. Blood (2007) 1.61
Prevention of transfusion of platelet components contaminated with low levels of bacteria: a comparison of bacteria culture and pathogen inactivation methods. Transfusion (2007) 1.60
A role of the fast ATP-gated P2X1 cation channel in thrombosis of small arteries in vivo. J Exp Med (2003) 1.56
Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy. Biol Blood Marrow Transplant (2011) 1.54
Successful mobilization of Ph-negative blood stem cells with intensive chemotherapy + G-CSF in patients with chronic myelogenous leukemia in first chronic phase. Leuk Lymphoma (2006) 1.52
MRS2500 [2-iodo-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate], a potent, selective, and stable antagonist of the platelet P2Y1 receptor with strong antithrombotic activity in mice. J Pharmacol Exp Ther (2005) 1.51
Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor? Blood (2010) 1.51
Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. Blood (2011) 1.50
Release of immune modulation factors from platelet concentrates during storage after photochemical pathogen inactivation treatment. Transfusion (2008) 1.47
Multiple-laboratory comparison of in vitro assays utilized to characterize hematopoietic cells in cord blood. Transfusion (2006) 1.43
The socioeconomic and psychosocial circumstances of adult long-term survivors of hematopoietic stem cell transplantation in childhood. Pediatr Transplant (2011) 1.42
Platelets photochemically treated with amotosalen HCl and ultraviolet A light correct prolonged bleeding times in patients with thrombocytopenia. Transfusion (2006) 1.41
The detection of platelet antibodies by simultaneous analysis of specific platelet antibodies and the monoclonal antibody-specific immobilization of platelet antigens: an interlaboratory comparison. Transfusion (2010) 1.40
Introduction of a quality management system and outcome after hematopoietic stem-cell transplantation. J Clin Oncol (2011) 1.38
Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation. Haematologica (2009) 1.34
Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood (2004) 1.31
Mesenchymal stromal cells from umbilical cord blood. Curr Stem Cell Res Ther (2007) 1.30
Metabolic impact of sex hormones on obesity. Brain Res (2010) 1.30
Megakaryocyte-restricted MYH9 inactivation dramatically affects hemostasis while preserving platelet aggregation and secretion. Blood (2007) 1.29
Endotoxin-free heat-shock protein 70 fails to induce APC activation. Eur J Immunol (2002) 1.28
Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry. Blood (2013) 1.27
The combination of colistin and doripenem is synergistic against Klebsiella pneumoniae at multiple inocula and suppresses colistin resistance in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother (2012) 1.25
Allogeneic hematopoietic stem-cell transplantation for myeloid sarcoma: a retrospective study from the SFGM-TC. J Clin Oncol (2008) 1.25
Signaling role for phospholipase C gamma 2 in platelet glycoprotein Ib alpha calcium flux and cytoskeletal reorganization. Involvement of a pathway distinct from FcR gamma chain and Fc gamma RIIA. J Biol Chem (2003) 1.24
A new ELISA kit which uses a combination of Plasmodium falciparum extract and recombinant Plasmodium vivax antigens as an alternative to IFAT for detection of malaria antibodies. Malar J (2007) 1.21
Birbeck granules are subdomains of endosomal recycling compartment in human epidermal Langerhans cells, which form where Langerin accumulates. Mol Biol Cell (2002) 1.21
A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup. Blood (2002) 1.21
Standards for the terminology and labeling of cellular therapy products. Transfusion (2007) 1.20
Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus. Clin Infect Dis (2012) 1.20
Respiratory syncytial virus infection in recipients of allogeneic stem-cell transplantation: a retrospective study of the incidence, clinical features, and outcome. Transplantation (2009) 1.20
Acute leukemia during pregnancy: a report on 37 patients and a review of the literature. Cancer (2005) 1.20
Importance of platelet phospholipase Cgamma2 signaling in arterial thrombosis as a function of lesion severity. Arterioscler Thromb Vasc Biol (2005) 1.20
Observing and engaging in purposeful actions with objects influences estimates of their size. Percept Psychophys (2004) 1.18
The incidence of hemorrhagic cystitis and BK-viruria in allogeneic hematopoietic stem cell recipients according to intensity of the conditioning regimen. Haematologica (2006) 1.15
Neuronal apoptosis-inhibitory protein does not interact with Smac and requires ATP to bind caspase-9. J Biol Chem (2004) 1.15
Lymphocyte recovery is a major determinant of outcome after matched unrelated myeloablative transplantation for myelogenous malignancies. Biol Blood Marrow Transplant (2009) 1.15
TDP-43, an ALS linked protein, regulates fat deposition and glucose homeostasis. PLoS One (2013) 1.14
Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood (2002) 1.14
NK cells expressing inhibitory KIR for non-self-ligands remain tolerant in HLA-matched sibling stem cell transplantation. Blood (2010) 1.14
Early and late invasive pneumococcal infection following stem cell transplantation: a European Bone Marrow Transplantation survey. Br J Haematol (2002) 1.13
Early immune response against retrovirally transduced herpes simplex virus thymidine kinase-expressing gene-modified T cells coinfused with a T cell-depleted marrow graft: an altered immune response? Hum Gene Ther (2008) 1.12
Microarray-based genotyping for blood groups: comparison of gene array and 5'-nuclease assay techniques with human platelet antigen as a model. Transfusion (2005) 1.10
A real-time TaqMan PCR for routine quantitation of cytomegalovirus DNA in crude leukocyte lysates from stem cell transplant patients. J Virol Methods (2003) 1.09
Factors influencing moderate to severe reactions to PLT transfusions: experience of the TRAP multicenter clinical trial. Transfusion (2003) 1.09
Differential regulation and relocalization of the platelet P2Y receptors after activation: a way to avoid loss of hemostatic properties? Mol Pharmacol (2004) 1.07
Clinical Protocols for the Isolation and Expansion of Mesenchymal Stromal Cells. Transfus Med Hemother (2008) 1.07
Rapid salvage treatment with virus-specific T cells for therapy-resistant disease. Clin Infect Dis (2012) 1.07
Screening of single-donor apheresis platelets for bacterial contamination: the PASSPORT study results. Transfusion (2009) 1.07
Identification of species of viridans group streptococci in clinical blood culture isolates by sequence analysis of the RNase P RNA gene, rnpB. J Infect (2008) 1.06
An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura. Br J Haematol (2006) 1.06
Hematopoietic growth factors--use in normal blood and stem cell donors: clinical and ethical issues. Transfusion (2008) 1.06
A prospective study of diagnosis of Toxoplasma gondii infection after bone marrow transplantation. APMIS (2008) 1.05
Altered gene expression in human adipose stem cells cultured with fetal bovine serum compared to human supplements. Tissue Eng Part A (2010) 1.05
Pathogen Inactivation of Platelet and Plasma Blood Components for Transfusion Using the INTERCEPT Blood System™ Transfus Med Hemother (2011) 1.04
Abnormal megakaryocyte morphology and proplatelet formation in mice with megakaryocyte-restricted MYH9 inactivation. Blood (2008) 1.04
Differential involvement of the P2Y1 and P2Y12 receptors in platelet procoagulant activity. Arterioscler Thromb Vasc Biol (2003) 1.03
The cellular pathway of CD1e in immature and maturing dendritic cells. Traffic (2005) 1.03
Correspondence of AQP4 expression and hypoxic-ischaemic brain oedema monitored by magnetic resonance imaging in the immature and juvenile rat. Eur J Neurosci (2004) 1.03
Streptococcus viridans septicaemia: a comparison study in patients admitted to the departments of infectious diseases and haematology in a university hospital. Scand J Infect Dis (2002) 1.03
Telehematology: a pilot experience of cytological diagnosis of acute myeloid leukemia via the Internet. A GOELAMS study. Haematologica (2006) 1.02